Michael E. Thase, MD

Treatment-Resistant Depression: Prevalence, Risk Factors, and Treatment Strategies

May 15, 2011

Michael E. Thase

Article

Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients: A Randomized, Open-Label Study

February 24, 2011

Read this article to examine results from a randomized, open-label, multicenter study that compared treatment outcomes with the serotonin-norepinephrine reuptake inhibitor venlafaxine extended release with selective serotonin reuptake inhibitors...

Michael E. Thase, Philip T. Ninan, Jeff J. Musgnung, et al

Review Article

Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled Trials

February 22, 2011

David J. Carpenter, Regan Fong, John E. Kraus, et al

Educational Activity

The Role of Neurobiologic Processes in Symptoms of Depression

February 15, 2011

Michael E. Thase

Original Research

Effectiveness and Safety of Vagus Nerve Stimulation for Severe Treatment-Resistant Major Depression in Clinical Practice After FDA Approval: Outcomes at 1 Year

January 11, 2011

Pilar Cristancho, Mario A. Cristancho, Gordon H. Baltuch, et al

Article

Clinical Relevance of Disturbances of Sleep and Vigilance in Major Depressive Disorder: A Review

December 30, 2010

Read this article to review the relationship between sleep disturbances and depression, the impact of antidepressant medications on sleep parameters, and the treatment options to address sleep abnormalities in...

Michael E. Thase, Harald Murck, Anke Post

Educational Activity

The Role of Neurobiologic Processes in Treating Depression

October 15, 2010

Michael E. Thase

Original Research

Safety and Tolerability Associated With Second-Generation Antipsychotic Polytherapy in Bipolar Disorder: Findings From the Systematic Treatment Enhancement Program for Bipolar Disorder

September 7, 2010

Joseph F. Goldberg, Terence A. Ketter, David J. Miklowitz, et al

Educational Activity

Performance Improvement CME: Improving Outcomes in Depression

August 15, 2010

Alan J. Gelenberg, Michael E. Thase

Original Research

Pharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence

August 10, 2010

Holly A. Swartz, Michael E. Thase

Original Research

Clinical Features Associated With Poor Pharmacologic Adherence in Bipolar Disorder: Results From the STEP-BD Study

March 15, 2010

Roy H. Perlis, Michael J. Ostacher, David J. Miklowitz, et al

Original Research

Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies

February 23, 2010

Mauricio Tohen, Michael Case, Madhukar H. Trivedi, et al

Treatment-Resistant Depression: Prevalence, Risk Factors, and Treatment Strategies

Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients: A Randomized, Open-Label Study

Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled Trials

The Role of Neurobiologic Processes in Symptoms of Depression

Effectiveness and Safety of Vagus Nerve Stimulation for Severe Treatment-Resistant Major Depression in Clinical Practice After FDA Approval: Outcomes at 1 Year

Clinical Relevance of Disturbances of Sleep and Vigilance in Major Depressive Disorder: A Review

The Role of Neurobiologic Processes in Treating Depression

Safety and Tolerability Associated With Second-Generation Antipsychotic Polytherapy in Bipolar Disorder: Findings From the Systematic Treatment Enhancement Program for Bipolar Disorder

Performance Improvement CME: Improving Outcomes in Depression

Pharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence

Clinical Features Associated With Poor Pharmacologic Adherence in Bipolar Disorder: Results From the STEP-BD Study

Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies

ELSEWHERE:

FOLLOW US:

Michael E. Thase, MD

Treatment-Resistant Depression: Prevalence, Risk Factors, and Treatment Strategies

Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients: A Randomized, Open-Label Study

Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled Trials

The Role of Neurobiologic Processes in Symptoms of Depression

Effectiveness and Safety of Vagus Nerve Stimulation for Severe Treatment-Resistant Major Depression in Clinical Practice After FDA Approval: Outcomes at 1 Year

Clinical Relevance of Disturbances of Sleep and Vigilance in Major Depressive Disorder: A Review

The Role of Neurobiologic Processes in Treating Depression

Safety and Tolerability Associated With Second-Generation Antipsychotic Polytherapy in Bipolar Disorder: Findings From the Systematic Treatment Enhancement Program for Bipolar Disorder

Performance Improvement CME: Improving Outcomes in Depression

Pharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence

Clinical Features Associated With Poor Pharmacologic Adherence in Bipolar Disorder: Results From the STEP-BD Study

Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression: Rapid Onset of Therapeutic Response and Its Predictive Value for Subsequent Overall Response in a Pooled Analysis of 5 Studies

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles